General Information of Drug (ID: DMZYCWT)

Drug Name
BCI-632 Drug Info
Synonyms
LFAGGDAZZKUVKO-JAGWWQSPSA-N; MGS-0039; CHEMBL186453; 569686-87-9; MGS0039; MGS 0039; SCHEMBL234576; GTPL1397; DTXSID40432407; BDBM50151435; (1R,2R,3R,5R,6R)-2-amino-3-[(3,4-dichlorophenyl)methoxy]-6-fluorobicyclo[310]hexane-2,6-dicarboxylic acid; (1r,2r,3r,5r,6r)-2-amino-3-(3,4-dichlorobenzyloxy)6-fluorobicyclo[310] hexane-2,6-dicarboxylic acid; (1R,2R,3R,5R,6R)-2-Amino-3-(3,4-dichlorobenzyloxy)-6-fluorobicyclo[310]hexane-2,6-dicarboxylic acid; (1R, 2R, 3R, 5R,
Indication
Disease Entry ICD 11 Status REF
Alzheimer disease 8A20 Phase 1 [1]
Major depressive disorder 6A70.3 Phase 1 [1]
Cross-matching ID
PubChem CID
9886034
CAS Number
CAS 569686-87-9
TTD Drug ID
DMZYCWT

Molecule(s) Related to This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Metabotropic glutamate receptor 2 (mGluR2) TTXJ47W GRM2_HUMAN Antagonist [2]
Metabotropic glutamate receptor 3 (mGluR3) TT8A9EF GRM3_HUMAN Modulator [2]

The Expression Level of Molecule(s) in Normal Tissue of Major ADME-Related Organs

Molecule Molecule Type Gene Name Liver Colon Kidney Small Intestine
Metabotropic glutamate receptor 2 (mGluR2) DTT GRM2 3.621 3.472 3.053 4.225
Metabotropic glutamate receptor 3 (mGluR3) DTT GRM3 4.733 4.24 4.672 3.573
Molecule Expression Atlas in Normal Tissue of Major ADME-related organs

The Expression Level of Molecule(s) between Disease Section and Healthy Individual Tissue

The Studied Disease Alzheimer disease
ICD Disease Classification 8A20
Molecule Name Molecule Type Gene Name p-value Fold-Change Z-score
Metabotropic glutamate receptor 2 (mGluR2) DTT GRM2 1.09E-01 -0.11 -0.2
Metabotropic glutamate receptor 2 (mGluR2) DTT GRM2 3.19E-01 -0.06 -0.34
Metabotropic glutamate receptor 3 (mGluR3) DTT GRM3 6.89E-02 -0.39 -0.17
Metabotropic glutamate receptor 3 (mGluR3) DTT GRM3 4.60E-02 -0.05 -0.15
Molecular Expression Atlas between Disease Section and Healthy Individual Tissue

References

1 ClinicalTrials.gov (NCT01548703) A Multiple Ascending Dose Study of BCI-838 in Healthy Volunteers. U.S. National Institutes of Health.
2 Synthesis, in vitro pharmacology, structure-activity relationships, and pharmacokinetics of 3-alkoxy-2-amino-6-fluorobicyclo[3.1.0]hexane-2,6-dicarboxylic acid derivatives as potent and selective group II metabotropic glutamate receptor antagonists. J Med Chem. 2004 Aug 26;47(18):4570-87.